COMMUNIQUÉS West-GlobeNewswire

Sanuwave Announces Q2 FY2025 Financial Results
08/08/2025
Q2 2025 revenues were $10.2 million , up 42% from $7.2 million in Q2 2024. This represents the highest Q2 quarterly revenues in Company history. Q2 2025 gross margin was 78.3% , versus 73.2% in Q2 2024. GAAP Operating [...]
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments
08/08/2025
Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company’s guidance range of between $17 million and $19 million SERB Pharmaceuticals to acquire Y-mAbs in $412.0 [...]
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance
08/08/2025
Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on an organic basis Total Rare Disease quarterly net revenues of $104.0 million, which [...]
Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility
08/08/2025
FDA-approved protocol update significantly expands patient eligibility criteria for the BACKBEAT global pivotal study (“BACKBEAT study”), resulting in an estimated more than 24-fold increase in the potentially eligible [...]
Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
08/08/2025
NEWTOWN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical [...]
Nicox étend sa ligne de financement flexible existante
08/08/2025
Communiqué de presse Nicox étend sa ligne de financement flexible existante 5 millions d’actions ajoutées à la ligne de financement en fonds propres existante avec Vester Finance Les premiers résultats de l’étude [...]
Nicox Extends Existing Flexible Equity Financing
08/08/2025
Press Release Nicox Extends Existing Flexible Equity Financing 5 million shares added to the existing equity financing line with Vester Finance NCX 470 Denali confirmatory Phase 3 results expected mid-August to mid- [...]
Orion Corporation: Managers’ transactions – Juhani Kankaanpää
08/08/2025
ORION CORPORATION MANAGERS’ TRANSACTIONS 8 AUGUST 2025 at 9.30 EEST Orion Corporation: Managers’ transactions – Juhani Kankaanpää Orion Corporation has received the following disclosure under Market Abuse Regulation (EU [...]
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025
08/08/2025
Tokyo, Japan and Cambridge, UK, 8 August 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter and first half [...]
Sai Life Sciences Limited Reports Revenue growth of 77% YoY
08/08/2025
Q1FY26 Revenue at ₹496 Cr; EBITDA at ₹125 Cr; Net Profit at ₹60 Cr HYDERABAD, India, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator focused, Contract Research, [...]
Coloplast A/S - 9M 2024/25 Earnings Release - Invitation to conference call on 19 August 2025 at 11.00am CEST
08/08/2025
Tuesday, 19 August 2025 at 11.00 - 12.00h CEST In connection with the publication of Coloplast’s interim financial results for 9M 2024/25, to be released same day in the morning around 07.30h CEST, Coloplast will host a [...]
Vistin Pharma ASA: Invitation to Q2 2025 conference call
08/08/2025
Oslo, Norway, 08 August 2025 Vistin Pharma ASA will release its second quarter and YTD 2025 results on Friday 15th of August 2025. Vistin Pharma will host a conference call for all shareholders and interested parties at [...]
Heartflow, Inc. Announces Pricing of Upsized Initial Public Offering
08/08/2025
MOUNTAIN VIEW, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the pricing of its upsized initial public [...]
BioVie Inc. Announces Pricing of $12 Million Public Offering
08/08/2025
CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions [...]
89bio Reports Second Quarter 2025 Financial Results and Corporate Updates
07/08/2025
– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 topline histology data expected in 1H 2027 and in 2028, respectively; each trial designed to support accelerated approval to treat patients with metabolic dysfunction [...]
Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance
07/08/2025
MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
07/08/2025
Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™ (paltusotine) New Drug Application with September 25, 2025 PDUFA Date Continued Progress on the Global Development [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
07/08/2025
CONSHOHOCKEN, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
07/08/2025
CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout expected 2H 2025 Fast Track Designated Ozuriftamab vedotin (Oz-V; [...]

Pages